Advertisement
Advertisement

SLS

SLS logo

SELLAS Life Sciences Group, Inc. Common Stock

1.16
USD
-0.11
-9.06%
Feb 24, 15:39 UTC -5
Closed
exchange

After-Market

1.145

-0.01
-0.87%

SELLAS Life Sciences Group, Inc. Common Stock Profile

About

SELLAS Life Sciences Group is a development-stage biopharmaceutical company. It focused on novel cancer immunotherapeutics for cancer indications. The company's product candidate, galinpepimut-S, is licensed from Memorial Sloan Kettering Cancer Center and targets the Wilms Tumor 1 protein, which is present in an array of tumor types. SELLAS Life Sciences Group Inc., formerly known as Galena Biopharma Inc., is based in NEW YORK, United States.

Info & Links

CEO

Angelos M. Stergiou

Headquarters

7 TIMES SQUARE, SUITE 2503
NEW YORK, NY 10036, UNITED STATES

Industry

Medical Biomedical And Genetics

Sector

Medical

Website

www.sellaslifesciences.com

Auditor

Moss Adams LLP

Share holders

35

Employees

16

SELLAS Life Sciences Group, Inc. Common Stock Statistics

Valuation Measures

Market Capitalization2

80.59M

Enterprise Value

59.46M

Enterprise Value/EBITDA(ttm)

-1.81

Price to Earnings Ratio(ttm)

--

Price to Sales(ttm)

--

Price to Book(mrq)

5.30

Price to Cash(ytd)

--

Profitability

Gross Margin(ttm)

0.00%

Operating Margin(ttm)

--

Profit Margin(ttm)

0.00%

Return on Equity(ttm)

-629.46%

Return on Invested Capital(ttm)

-297.94%

Return on Assets(ttm)

-178.65%

Income Statement

Revenue(ttm)

0.00

Revenue Per Share(ttm)

0.00

Gross Profit(ttm)

0.00

EBITDA(ttm)3

-32.77M

Net Income Available to Common(ttm)

-32.28M

Diluted EPS(ttm)

-0.69

Share Statistics

Beta (5Y Monthly)

2.42

52-Week Change

23.37%

S&P 500 52-Week Change

18.02%

S&P 500 Member

Yes

Stock Optionable

Yes

Total Shares Outstanding1

70.38M

Dividend Yield

0.00%

Float4

69.54M

% Held by Insiders

1.20%

% Held by Institutions

17.38%

Balance Sheet

Total Cash(mrq)

21.13M

Total Cash Per Share(mrq)

0.30

Total Debt(mrq)

0.00

Total Debt/Equity(mrq)

0.00%

Current Ratio(mrq)

2.26%

Quick Ratio(mrq)

2.26%

Book Value Per Share(mrq)

0.25

Cash Flow

Operating Cash Flow Per Share(ytd)

-0.41

Free Cash Flow(ytd)

-28.25M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.

  • 1 Total Shares outstanding is taken from the most recently filed quarterly or annual report.
  • 2 Market Cap is calculated using total shares outstanding and the most recent share price.
  • 3 EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
  • 4 The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.
Advertisement